Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 5/20 | 0.35 |
| ▸ | MAG | P20916 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CD69 | Q07108 | 1/20 | 0.30 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8539918 | 1.00 | NOD2 (0.55) | NOD2MAPK1ESR1PGRHTR1A | |
| SCHEMBL4450131 | 0.94 | NOD2 (0.55) | NOD2MAPK1ESR1PGRHTR1A | |
| SCHEMBL342953 | 0.93 | NOD2 (0.57) | NOD2MAPK1ESR1PGRHTR1A | |
| SCHEMBL5270133 | 0.93 | NOD2 (0.57) | NOD2MAPK1ESR1PGRHTR1A | |
| SCHEMBL3229330 | 0.93 | NOD2 (0.57) | NOD2MAPK1ESR1PGRHTR1A | |
| Water SCHEMBL769017 | 0.93 | NOD2 (0.57) | NOD2MAPK1ESR1PGRHTR1A | |
| SCHEMBL14761523 | 0.92 | NOD2 (0.58) | NOD2MAPK1ESR1PGRHTR1A | |
| Alanine SCHEMBL11120060 | 0.92 | NOD2 (0.56) | NOD2MAPK1ESR1PGRHTR1A | |
| SCHEMBL19435442 | 0.92 | NOD2 (0.44) | NOD2MAPK1ESR1PGRHTR1A | |
| SCHEMBL4452390 | 0.91 | NOD2 (0.55) | NOD2MAPK1ESR1PGRHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7600 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4487869-A2 | RNA ENCODING A TUMOR ANTIGEN | CureVac SE (DE) | 2025-01-08 | — | — | EP | claimed |
| US-20240091344-A1 | MERS CORONAVIRUS VACCINE | CureVac SE (DE) | 2024-03-21 | — | — | US | claimed |
| US-20210401971-A1 | MERS CORONAVIRUS VACCINE | CUREVAC AG (DE) | 2021-12-30 | — | — | US | claimed |
| EP-3777881-A1 | RNA ENCODING A TUMOR ANTIGEN | CureVac AG (DE) | 2021-02-17 | — | — | EP | claimed |
| US-20210030864-A1 | BUNYAVIRALES VACCINE | CureVac SE (DE) | 2021-02-04 | — | — | US | claimed |
| EP-3673069-A1 | BUNYAVIRALES VACCINE | CureVac AG (DE) | 2020-07-01 | — | — | EP | claimed |
| US-20200085942-A1 | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT | CUREVAC AG (DE) | 2020-03-19 | — | — | US | claimed |
| US-20200016264-A1 | NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | CUREVAC AG (DE) | 2020-01-16 | — | — | US | claimed |
| US-20190351048-A1 | MERS CORONAVIRUS VACCINE | CureVac SE (DE) | 2019-11-21 | — | — | US | claimed |
| US-20190351044-A1 | LASSA VIRUS VACCINE | CureVac SE (DE) | 2019-11-21 | — | — | US | claimed |
| EP-0135376-B1 | POLYOXYPROPYLENE-POLYOXYETHYLENE BLOCK POLYMER BASED ADJUVANTS AND VACCINES USING THEM | SYNTEX (U.S.A.) INC. (US) | 1990-11-07 | — | — | EP | claimed |
| US-4933179-A | IMMUNOLOGY | SYNTEX (U.S.A.) INC. (US) | 1990-06-12 | — | — | US | claimed |
| EP-0329609-A2 | Antiviral combination | CIBA-GEIGY AG (CH) | 1989-08-23 | — | — | EP | claimed |
| US-4857318-A | Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis | SYNTEX (U.S.A.) INC. (US) | 1989-08-15 | — | — | US | claimed |
| EP-0315153-A2 | Vaccine adjuvant | SYNTEX (U.S.A.) INC. (US) | 1989-05-10 | — | — | EP | claimed |
| US-4772466-A | ANTIGEN, GLYCOL ETHER-BASED SURFACTANT, IMMUNOSTIMULATING GLYCOPEPTIDE AND METABOLIZABLE NONTOXIC OIL | SYNTEX (U.S.A.) INC. (US) | 1988-09-20 | — | — | US | claimed |
| US-4770874-A | EMULSIFYING AN ANTIGEN WITH AN IMMUNOSTIMULATING GLYCOPEPTIDE, POLYETHER BLOCK COPOLYMER, GLYCOL ETHER-BASED SURFACTANT, BUFFERED SALINE SOLUTION; VACINE | SYNTEX (U.S.A.) INC. (US) | 1988-09-13 | — | — | US | claimed |
| US-4606918-A | IMMUNOSTIMULATING GLYCOPEPTIDE; EMULSIFICATION | SYNTEX (U.S.A.) INC. (US) | 1986-08-19 | — | — | US | claimed |
| US-4522811-A | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides | SYNTEX (U.S.A.) INC. (US) | 1985-06-11 | — | — | US | claimed |
| EP-0135376-A2 | Polyoxypropylene-polyoxyethylene block polymer based adjuvants and vaccines using them | SYNTEX (U.S.A.) INC. (US) | 1985-03-27 | — | — | EP | claimed |